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ABSTRACT
Objectives To compare the safety, reactogenicity, and
immunogenicity of an adjuvanted split virion H1N1
vaccine and a non-adjuvanted whole virion vaccine used
in the pandemic immunisation programme in the United
Kingdom.
Design Open label, randomised, parallel group, phase II
study.
Setting Five UK centres (Oxford, Southampton, Bristol,
Exeter, and London).
Participants Children aged 6months to less than 13 years
for whom a parent or guardian had provided written
informed consent andwhowere able to complywith study
procedures were eligible. Those with laboratory
confirmed pandemic H1N1 influenza or clinically
diagnosed disease meriting antiviral treatment, allergy to
egg or any other vaccine components, or coagulation
defects, or who were severely immunocompromised or
had recently received blood products were excluded.
Children were grouped by age: 6 months-<3 years
(younger group) and 3-<13 years (older group).
Recruitment was by media advertising and direct mailing.
Recruitment visits were attended by 949 participants, of
whom 943 were enrolled and 937 included in the per
protocol analysis.
Interventions Participants were randomised 1:1 to
receive AS03B (tocopherol based oil in water emulsion)
adjuvanted split virion vaccine derived fromegg culture or
non-adjuvanted whole virion vaccine derived from cell
culture. Both were given as two doses 21 days apart.
Reactogenicity data were collected for one week after
immunisation by diary card. Serum samples were
collected at baseline and after the second dose.
Main outcome measures Primary reactogenicity end
points were frequency and severity of fever, tenderness,
swelling, and erythemaafter vaccination. Immunogenicity
was measured by microneutralisation and
haemagglutination inhibition assays. The primary
immunogenicity objective was a comparison between
vaccines of the percentage of participants showing
seroconversion by themicroneutralisation assay (fourfold
rise to a titre of ≥1:40 from before vaccination to three
weeks after the second dose).
Results Seroconversion rates were higher after the
adjuvanted split virion vaccine than after the whole virion
vaccine, most notably in the youngest children (163 of
166participantswith paired serumsamples (98.2%, 95%
confidence interval 94.8% to 99.6%) v 157 of 196
(80.1%, 73.8% to 85.5%), P<0.001) in children under
3 years and 226 of 228 (99.1%, 96.9% to 99.9%) v
95.9%, 92.4% to 98.1%, P=0.03) in those over 3 years).
The adjuvanted split virion vaccine was more reactogenic
than the whole virion vaccine, with more frequent
systemic reactions and severe local reactions in children
aged over 5 years after dose one (13 (7.2%, 3.9% to 12%)
v 2 (1.1%, 0.1% to 3.9%), P<0.001) and dose two (15
(8.5%, 4.8% to 13.7%) v 2 (1.1%, 0.1% to 4.1%),
P<0.002) and after dose two in those under 5 years (15
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(5.9%, 3.3% to 9.6%) v 0 (0.0%, 0% to 1.4%), P<0.001).
Dose two of the adjuvanted split virion vaccine was more
reactogenic than dose one, especially for fever ≥38ºC in
those aged under 5 (24 (8.9%, 5.8% to 12.9%) v 57
(22.4%, 17.5% to 28.1%), P<0.001).
Conclusions In this first direct comparison of an AS03B
adjuvanted split virion versus whole virion non-
adjuvanted H1N1 vaccine, the adjuvanted vaccine, while
more reactogenic, was more immunogenic and,
importantly, achieved high seroconversion rates in
children aged less than 3 years. This indicates the
potential for improved immunogenicity of influenza
vaccines in this age group.
Trial registration Clinical trials.gov NCT00980850;
ISRCTN89141709.
INTRODUCTION
During the 2009-10 influenza A (H1N1) pandemic,
children experienced pandemic A(H1N1) infections
at four times the rate of adults and were more com-
monly admitted to hospital.1 2 Although most cases in
children were mild, severe disease and deaths
occurred, mainly in those with comorbidities.2 3 This,
along with the role that children play in virus
transmission45 made children a priority group for vac-
cination against pandemic influenza in many
countries.5 Some countries routinely vaccinate chil-
dren against seasonal influenza,6 but this strategy is
compromised by the limited immunogenicity and effi-
cacy of inactivated seasonal influenza vaccines in
children.7 8 In the United Kingdom, seasonal influenza
vaccinationwith inactivated split virion or surface anti-
gens vaccines is recommended only for children with
comorbidities who are deemed at high risk, with chil-
dren receiving two doses in their first year of vaccina-
tion and one thereafter. While there are substantial
safety data regarding the use of trivalent seasonal split
and subunit non-adjuvanted inactivated influenza vac-
cines in children, similar data on safety and efficacy for
novel H1N1 vaccines were lacking9-12 and only limited
data from H5N1 “mock-up” vaccines were available.5
Novel adjuvants had not been routinely used in early
childhood before this pandemic but were believed to
provide enhanced immunogenicity, particularly in
infants in whom traditional influenza vaccines have
limited efficacy,7 and potentially allow antigenic spar-
ing and induction of cross clade immunity.13-15
While the H5N1 “mock-up” whole virion vaccines
were well tolerated,16 whole virion influenza vaccines
have previously been associated with unacceptable
reactogenicity rates.7 Cell culture for manufacture of
influenza vaccines should shorten production times by
avoiding the bottleneck caused by the supply of hens’
eggs17 and avoid reactions in those allergic to eggs.18
The UK Department of Health purchased two
H1N1 vaccines for the national immunisation pro-
gramme, an AS03B adjuvanted split virion vaccine
derived from egg culture and a non-adjuvanted whole
virion vaccine derived from Vero cell culture.17 We
evaluated the safety, tolerability, and immunogenicity
of the two vaccines in children aged 6 months to
12 years to inform the scientific community, policy
makers, and parents.
METHODS
Vaccines
We compared two novel H1N1 vaccines: an AS03B
adjuvanted split virion vaccine (GlaxoSmithKline
Vaccines, Rixensart, Belgium) and a non-adjuvanted
whole virion vaccine (Baxter Vaccines, Vienna). The
adjuvanted split virion vaccine was constructed from
the A/California/7/2009 (H1N1) v-like strain antigen
(New York Medical College x-179A), generated by
classical re-assortment in eggs, combining the HA,
NA, and PB1 genes of A/California/7/2009 (H1N1)v
with the PR8 strain backbone.12 19 Each dose (0.25 ml,
half the adult dose) contained 1.875 μg of haemagglu-
tinin antigen, the oil in water emulsion based adjuvant
AS03B (containing squalene (5.345 mg), DL alpha
tocopherol (5.93 mg), and polysorbate 80 (2.43 mg))
and thiomersal and was supplied as suspension and
emulsion multidose vials.
The non-adjuvanted whole virion vaccine, derived
fromVero cell culture, was supplied inmultidose vials.
Opened vials were used within three hours; each dose
(0.5ml) contained 7.5 μg of haemagglutinin from influ-
enza A/California/07/2009 (H1N1).
Study design
Between 26 September and 11December 2009, during
the second wave of the influenza A (H1N1) pandemic
in the UK, we conducted an open label, randomised,
parallel group, phase II study at five UK sites (Oxford,
Bristol, Southampton,Exeter, andLondon) in children
aged 6 months to 12 years to compare the safety, reac-
togenicity, and immunogenicity of two novel H1N1
vaccines in a two dose regimen.
Recruitment by media advertising and direct mail-
ing began on 26 September, before the start of the UK
pandemic influenza immunisation programme. Enrol-
ment continued during the initial phase of the national
programme targeting immunisation of children in high
risk groups. Extensionof thenational programme to all
children under the age of 5 years occurred after the end
of study enrolment. Parents or guardians gave written
informed consent, and children aged 6 months to less
than 13 years for whom a parent or guardian had pro-
vided written informed consent and who were able to
comply with study procedures were eligible for inclu-
sion. We also sought verbal assent from children aged
7 years and older. To target an immunologically naive
population we excluded those with laboratory con-
firmed pandemic H1N1 influenza or with clinically
diagnosed disease meriting antiviral treatment. For
safety reasons, those with allergy to egg or any other
vaccine components and coagulation defects were
excluded. Other exclusions included those who were
severely immunocompromised, were receiving immu-
nosuppressive treatment, had recently received blood
products, were going to be immunised with another
H1N1 vaccine, or were taking part in another clinical
trial. Participants were grouped into those aged
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6 months to less than 3 years (younger group) and
3 years to less than 13 years (older group).
Randomisation and masking
Children were stratified for age group and randomly
assigned in a 1:1 ratio to receive one of the two vac-
cines. Randomisation was in block sizes of 10, which
were generated by a statistician who was not directly
involved in enrolment. Assignment was by sequen-
tially numbered, identical, opaque sealed envelopes.
Procedures
Vaccines were administered by intramuscular injec-
tion (deltoid or anterior-lateral thigh depending on
age and muscle bulk) at enrolment and at day 21
(plus or minus 7 days). A minimum interval of
14 days between doses was allowed to reduce dropout
rates, to facilitate the rapid data collection that was
needed in this study setting, and to provide protection
as early as possible in the context of the pandemic.
Serum samples were collected immediately before
vaccination (study day 0) and 21 days (−7 to 14) after
second vaccination.
Up to the seventh day after vaccination parents or
guardians used diary cards to record axillary tempera-
ture, reactions at the injection site, solicited and unso-
licited systemic symptoms, and medications given
(including antipyretics/analgesics). Primary reacto-
genicity end points were frequency and severity of
fever, tenderness, swelling, and erythema after vacci-
nation. Secondary end points were the frequency and
severity of non-febrile solicited systemic reactions or
use of analgesics/antipyretics. Solicited systemic reac-
tions were different in those aged under and over
5 years to reflect the child’s ability to articulate symp-
toms. Erythema and swelling were graded by diameter
as mild (1-24 mm), moderate (25-29 mm), or severe
(≥50 mm). Other reactions were graded by effect on
daily activity as none, mild (transient reaction, no lim-
itation in activity), moderate (some limitations), or
severe (unable to perform normal activities) or by fre-
quency/duration into none, mild, moderate, and
severe categories.
Medically important adverse events (ongoing soli-
cited reactions or events necessitating a doctor’s visit
or study withdrawal after day seven after vaccination)
were recordedonadiary card.Wealsoundertookmon-
itoring of adverse events of special interest, as recom-
mended by the European Medicines Agency,20 and a
datamonitoring committeemonitored safety. Stopping
procedures were in place but were not required. All
data from case report forms and participant diary
cards were double entered and verified on computer.
Antibody responses were detected by microneutra-
lisation and haemagglutination inhibition with 0.5%
turkey erythrocytes by using standard methods21 22 at
the Centre for Infections, Health Protection Agency.
Assays were performed with egg grown reverse genet-
ics NIBRG-121 virus containing haemagglutinin and
neuraminidase from A/California/7/2009 (H1N1v);
the seed virus was supplied by the National Institute
for Biological Standards and Controls (NIBSC). The
negative control was pooled human sera, and the posi-
tive control was ferret antisera raised to A/California/
7/2007 (NIBSC). For haemagglutination inhibition,
serum samples were treated with receptor destroying
enzyme (RDEII) and initial dilution was 1:8. Samples
were titrated to determine absolute end point titres: for
samples that showed titres ≥1024, a further dilution
series was performed ending at a dilution of 1:16 384.
Formicroneutralisation, the initial dilutionof heat trea-
ted sera was 1:10. The final dilution was 1:320, unless
further dilutions were necessary to determine fourfold
rises from baseline. The neutralisation assay was per-
formed by infection of a MDCK cell suspension, and
final infectivity was detected by the use of monoclonal
antibody directed against influenza nucleoprotein in
an enzyme immunoassay detection format. Serum
samples were tested in duplicate and the geometric
mean value for each pair used.
The primary immunogenicity objective was a com-
parison between vaccines of the percentage of partici-
pants showing seroconversion by the microneutralisa-
tion assay, with seroconversion defined as a fourfold
rise to a titre of ≥1:40 from before the vaccination to
three weeks after the second dose. A secondary objec-
tive based on themicroneutralisation assay was a com-
parison between vaccines of the percentage with titres
≥1:40 after the second dose. Further secondary objec-
tives based on the haemagglutination inhibition assay
were comparisons between vaccines in the percentage
with fourfold rises to titres ≥1:32, the percentage with
titres ≥1:32, geometric mean rises from baseline, and
geometric mean titres, all after the second dose.
Statistical analysis
With 200 participants in each age and vaccine group
the study had 80% power to detect differences of −14%
to 12% around a 70% reactogenicity and seroconver-
sion rate. Planned recruitment was up to 250 partici-
pants per group to allow for drop out and non-
availability of serum samples.
For eachageandvaccinegroupwecalculatedpropor-
tions with local or systemic reactions and with serocon-
version or titres above given thresholds. Comparisons
between vaccines were made with a two sided Fisher’s
exact test. For reactions, we used the sign test for paired
data for comparisons between doses.
Geometricmean haemagglutination inhibition titres
and rises were calculated for each age and vaccine
group along with 95% confidence intervals. Logged
haemagglutination inhibition titres after vaccination
were compared between vaccines by using normal
errors regression in a univariable model and then in a
multivariable model with adjustment for age, study
site, sex, and interval from second vaccine dose to
obtaining final serum sample. The interaction between
age and vaccine was also investigated.
A planned interim analysis on the reactogenicity
data from the first 500 participants was performed to
provide rapid data to the UK Department of Health.
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The study site investigators remained blinded to the
results of this analysis while visits were ongoing.
Data analysis was undertaken with Stata software,
version 10. The level of significance was 5%. The
data were analysed per protocol. As planned, we did
not conduct intention to treat analyses because fewer
than 10% of participants would have been classified
differently in such an analysis.
RESULTS
Recruitment visits were attended by 949 participants,
of whom 943 were enrolled and 937 were included in
the per protocol analysis (fig 1 and table 1). Of these,
913 received the second vaccine dose per protocol at a
mean interval of 20 days (range 14-28 days). Serum
sampleswere obtained in 839 participants after the sec-
ond vaccine dose as per protocol at a mean interval of
20 days (14-35). For one participant a second dose
hamagglutination inhibition titre but not microneutra-
lisation titre was available and for two participants a
microneutralisation titre result, but no haemagglutina-
tion inhibition titre result, was available. Vials of the
adjuvanted split virion vaccine were used within
12 hours of opening and vials of the whole virion vac-
cine within three hours of opening.
Safety and tolerability
Tables 2 and 3 provide data on solicited reactions. The
adjuvanted split virion vaccine was associated with
more frequent severe local reactions than the whole
virion vaccine after either dose in those aged over
5 years (7.2% v 1.1%, P<0.001, for dose one; 8.5% v
1.1%, P=0.002, for dose two) and after dose two in
those under 5 years (5.9% v 0.0%, P<0.001). There
were also more systemic reactions among participants
aged 6 months to less than 5 years, with more irritabil-
ity after either dose (45.6% v 35.5% for dose one; 48% v
28.4% for dose two) and more decreased feeding
(40.6% v 29.9%) and decreased activity (31.9% v
17.3%) after dose two. Participants aged over 5 years
experiencedmoremuscle pain after either dose (32.6%
v 13.8% for dose one; 25% v 12.6% for dose two) and
were more often generally unwell after dose two
(26.1% v 14.9%).
In younger children, dose two of the adjuvanted split
virion vaccine was more reactogenic than dose one,
with more fever ≥38°C (22.4% v 8.9%, P<0.001),
Aged 3 to 12 years (n=502)Aged 6 months to <3 years (n=441)
Assessed for eligibility (n=949)
Randomised (n=943)
Randomised to receive adjuvanted split
  virion vaccine (n=212):
    Received first vaccine dose as per
      protocol (n=210)
    Administered whole virion vaccine
      (excluded) (n=1)
    Refused vaccination (n=1)
Received second vaccine dose as per
  protocol (n=204)
    Withdrew consent (n=1)
    Lost to follow-up (n=1)
    Withdrawn for medical reasons (n=1)
    Out of protocol time lines (n=3)
Randomised to receive whole virion
  vaccine (n=229):
    Received first vaccine dose as per
      protocol (n=229)
Randomised to receive  adjuvanted split
  virion vaccine (n=257):
    Received first vaccine dose as per
      protocol (n=254)
    Refused vaccination (n=1)
    Administered incorrect dose (n=2)
Randomised to receive whole cell
  vaccine (n=245):
    Received first vaccine dose as per
      protocol (n=244)
    Refused vaccination (n=1)
Serum sample obtained in 191
Completed and returned
diary cards (n=205)
Received second vaccine dose as per
  protocol (n=224)
    Lost to follow-up (n=1)
    Out of protocol time lines (n=4)
blood draw (n=4)
Serum sample obtained in 177
  Withdrew consent (n=6)
  Failed blood draw (n=21)
Serum sample obtained in 207
  Withdrew consent (n=8)
  Failed blood draw (n=9)
Serum sample obtained in 235
  Withdrew consent (n=2)
  Out of time line (n=2)
  Failed blood draw (n=9)
Serum sample obtained in 220
  Withdrew consent (n=3)
  Out of time line (n=2)
  Failed blood draw (n=12)
Serum sample obtained in 216
Completed and returned
diary cards (n=225)
Received second vaccine dose as per
  protocol (n=248)
    Withdrew consent (n=1)
    Lost to follow-up (n=1)
    Withdrawn for medical reasons (n=1)
    Out of protocol time lines (n=3)
Serum sample obtained in 244
Completed and returned
diary cards (n=246)
Received second vaccine dose as per
  protocol (n=237)
    Withdrew consent (n=3)
    Lost to follow-up (n=1)
    Out of protocol time lines (n=3)
Serum sample obtained in 240
Completed and returned
diary cards (n=235)
Completed and returned
diary cards (n=195)
Completed and returned
diary cards (n=219)
Completed and returned
diary cards (n=235)
Completed and returned
diary cards (n=227)
Excluded (n=6):
  Refused blood draw (n=4)
  Previous H1N1 influenza (n=1)
  Unwell on day of visit (n=1)
Fig 1 | Enrolment and follow-up of study participants
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local severe reactions (5.9% v 1.5%, P=0.02), and
decreased activity (31.9% v 20.4%, P<0.001). The sec-
ond dose of the whole virion vaccine was associated
with decreased frequency of being generally unwell
(14.9% v 24.9% after first dose).
In keeping with the increased reactogenicity of the
adjuvanted split virion vaccine, more recipients of that
vaccine received antipyretics/analgesics after either
dose of vaccine in the older children (36.5% v 22.1%
in the whole virion group for dose one; 28.4% v 16.6%
for dose two) and after the second dose in younger chil-
dren (43.7% v 23.6%, P<0.001) (table 3).
Four adverse events of special interest occurred, one
in a child receiving the whole virion vaccine (focal sei-
zure, considered unrelated to vaccination) and three in
participants receiving the adjuvanted split virion vac-
cine (one reactive knee arthritis, possibly related to
vaccination, and two generalised seizures considered
unrelated to vaccination). The reactive knee arthritis
occurred in a child aged 11 months in the leg in
which vaccine had been administered two days pre-
viously. The child became febrile on the evening of
vaccination and was failing to bear weight two days
later.Other joints and the vaccination site were normal
as were results of blood tests and x ray investigation of
the knee and pelvis. Throat swab and blood cultures
yielded sterile results. The child made a full recovery
after 10 days.
Five other serious adverse events occurred, but they
were not in the category of adverse events of special
interest and were considered unrelated to vaccination.
Immunogenicity
Before vaccination, 35 (4.0%) children (2.9% younger
group, 5.0% older group) had microneutralisation
titres ≥1:40, suggesting pre-existing immunity.
Tables 4, 5, and 6 and figure 2 show antibody
responses.
Seroconversion rates were higher with the adju-
vanted split virion vaccine than with the whole virion
unadjuvanted vaccine both by microneutralisation
assay (younger group 98.2% v 80.1% (P<0.001), older
group 99.1% v 95.9% (P=0.03), table 4) and haemag-
glutination inhibition assay (younger group 99.4% v
64.0%, older group 98.7% v 88.5%; P≤0.001 for both
groups, table 5). Compared with the whole virion vac-
cine, the adjuvanted split virion vaccinewas associated
with a higher percentage of participants with micro-
neutralisation titres ≥1:40 (99.3% v 88.5%; P<0.001),
a higher percentage with haemagglutination inhibition
titre ≥1:32 (99.3% v 78.2%; P<0.001), higher geometric
mean haemagglutination inhibition titres (411.0 v
69.3), and greater geometric rise in haemagglutination
inhibition titre from baseline (89.5 v 15.0) (P<0.001 for
all comparisons).
The multivariable analysis on logged haemaggluti-
nation inhibition titres showed a significant interaction
between age and vaccine (P<0.001), with 10.5-fold
(95% confidence interval 8.1 to 13.5) titres induced
by the adjuvanted split virion vaccine in the younger
participants comparedwith 3.6-fold (3.0 to 4.3) titres in
older children. We further evaluated this difference in
the age effect by vaccine by including age as a contin-
uous variable in themultivariable model. This showed
Table 1 | Baseline characteristics of children in study by age and vaccine. Figures are numbers of children unless specified
otherwise
Age 6 months-<3 years Age 3-12 years
Adjuvanted split
virion (n=210)
Whole virion
(n=229)
Adjuvanted split
virion (n=254)
Whole virion
(n=244)
Race or ethnic group:
White 189 201 231 222
Indian 0 1 0 0
Pakistani 1 0 2 1
Asian other 1 2 1 0
Mixed ethnic group 14 19 9 10
Black African 1 3 3 3
Black Caribbean 2 0 3 1
Chinese 0 0 2 2
Other 2 3 3 5
Sex:
Male 116 123 131 121
Female 94 106 123 123
Previous seasonal influenza vaccine 5 5 22 28
Median (range) age (months) 23 (6-35) 23 (6-35) 82 (36-151) 84 (36-155)
Site:
Bristol 44 46 41 42
Exeter 16 23 24 19
Oxford 70 79 66 59
Southampton 67 58 72 80
St Georges 13 23 51 44
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Table 2 | Local and systemic reactions in children aged 6 months to <5 years by vaccine and dose. Figures are numbers
(percentage, 95% confidence interval)
Adjuvanted split virion Whole virion vaccine
Dose 1 Dose 2 Dose 1 Dose 2
Total vaccinated 278 275 286 285
With diary card 270 254 279 271
Pain:
Mild 77 (28.5, 23.2 to 34.3) 79 (31.1, 25.5 to 37.2) 48 (17.2, 13 to 22.2) 46 (17, 12.7 to 22)
Moderate 6 (2.2, 0.8 to 4.8) 19 (7.5, 4.6 to 11.4) 3 (1.1, 0.2 to 3.1) 1 (0.4, 0 to 2)
Severe 2 (0.7, 0.1 to 2.7) 2 (0.8, 0.1 to 2.8) 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)
Any 85 (31.5, 26 to 37.4)*† 100 (39.4, 33.3 to 45.7)*† 51 (18.3, 13.9 to 23.3)* 47 (17.3, 13 to 22.4)*
Redness (mm):
1-24 67 (24.8, 19.8 to 30.4) 59 (23.2, 18.2 to 28.9) 64 (22.9, 18.1 to 28.3) 52 (19.2, 14.7 to 24.4)
25-49 9 (3.3, 1.5 to 6.2) 8 (3.1, 1.4 to 6.1) 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)
≥50 0 (0, 0 to 1.4) 11 (4.3, 2.2 to 7.6) 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)
Any 76 (28.1, 22.9 to 33.9) 78 (30.7, 25.1 to 36.8)* 64 (22.9, 18.1 to 28.3) 52 (19.2, 14.7 to 24.4)*
Swelling (mm):
1-24 42 (15.6, 11.4 to 20.4) 37 (14.6, 10.5 to 19.5) 26 (9.3, 6.2 to 13.4) 17 (6.3, 3.7 to 9.9)
25-49 8 (3, 1.3 to 5.8) 6 (2.4, 0.9 to 5.1) 0 (0, 0 to 1.3) 1 (0.4, 0 to 2)
≥50 2 (0.7, 0.1 to 2.7) 7 (2.8, 1.1 to 5.6) 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)
Any 52 (19.3, 14.7 to 24.5)* 50 (19.7, 15 to 25.1)* 26 (9.3, 6.2 to 13.4)* 18 (6.6, 4 to 10.3)*
Any local severe 4 (1.5, 0.4 to 3.7)† 15 (5.9, 3.3 to 9.6)*† 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)*
Decreased feeding:
Mild 67 (24.8, 19.8 to 30.4) 70 (27.6, 22.2 to 33.5) 75 (26.9, 21.8 to 32.5) 59 (21.8, 17 to 27.2)
Moderate 17 (6.3, 3.7 to 9.9) 27 (10.6, 7.1 to 15.1) 17 (6.1, 3.6 to 9.6) 14 (5.2, 2.9 to 8.5)
Severe 5 (1.9, 0.6 to 4.3) 6 (2.4, 0.9 to 5.1) 2 (0.7, 0.1 to 2.6) 8 (3, 1.3 to 5.7)
Any 89 (33, 27.4 to 38.9) 103 (40.6, 34.5 to 46.9)* 94 (33.7, 28.2 to 39.6) 81 (29.9, 24.5 to 35.7)*
Decreased activity:
Mild 34 (12.6, 8.9 to 17.2) 45 (17.7, 13.2 to 23) 26 (9.3, 6.2 to 13.4) 33 (12.2, 8.5 to 16.7)
Moderate 17 (6.3, 3.7 to 9.9) 33 (13, 9.1 to 17.8) 24 (8.6, 5.6 to 12.5) 11 (4.1, 2 to 7.1)
Severe 4 (1.5, 0.4 to 3.7) 3 (1.2, 0.2 to 3.4) 2 (0.7, 0.1 to 2.6) 3 (1.1, 0.2 to 3.2)
Any 55 (20.4, 15.7 to 25.7)† 81 (31.9, 26.2 to 38)*† 52 (18.6, 14.2 to 23.7) 47 (17.3, 13 to 22.4)*
Increased irritability:
Mild 89 (33, 27.4 to 38.9) 84 (33.1, 27.3 to 39.2) 64 (22.9, 18.1 to 28.3) 45 (16.6, 12.4 to 21.6)
Moderate 28 (10.4, 7 to 14.6) 34 (13.4, 9.5 to 18.2) 28 (10, 6.8 to 14.2) 26 (9.6, 6.4 to 13.7)
Severe 6 (2.2, 0.8 to 4.8) 4 (1.6, 0.4 to 4) 7 (2.5, 1 to 5.1) 6 (2.2, 0.8 to 4.8)
Any 123 (45.6, 39.5 to 51.7)* 122 (48, 41.7 to 54.4)* 99 (35.5, 29.9 to 41.4)* 77 (28.4, 23.1 to 34.2)*
Persistent crying:
Mild 52 (19.3, 14.7 to 24.5) 49 (19.3, 14.6 to 24.7) 32 (11.5, 8 to 15.8) 35 (12.9, 9.2 to 17.5)
Moderate 8 (3, 1.3 to 5.8) 13 (5.1, 2.8 to 8.6) 12 (4.3, 2.2 to 7.4) 13 (4.8, 2.6 to 8.1)
Severe 1 (0.4, 0 to 2) 1 (0.4, 0 to 2.2) 2 (0.7, 0.1 to 2.6) 1 (0.4, 0 to 2)
Any 61 (22.6, 17.7 to 28.1) 63 (24.8, 19.6 to 30.6) 46 (16.5, 12.3 to 21.4) 49 (18.1, 13.7 to 23.2)
Vomiting:
Mild 28 (10.4, 7 to 14.6) 28 (11, 7.5 to 15.5) 29 (10.4, 7.1 to 14.6) 26 (9.6, 6.4 to 13.7)
Moderate 6 (2.2, 0.8 to 4.8) 5 (2, 0.6 to 4.5) 3 (1.1, 0.2 to 3.1) 3 (1.1, 0.2 to 3.2)
Severe 0 (0, 0 to 1.4) 0 (0, 0 to 1.4) 0 (0, 0 to 1.3) 0 (0, 0 to 1.4)
Any 34 (12.6, 8.9 to 17.2) 33 (13, 9.1 to 17.8) 32 (11.5, 8 to 15.8) 29 (10.7, 7.3 to 15)
Diarrhoea:
Mild 54 (20, 15.4 to 25.3) 49 (19.3, 14.6 to 24.7) 58 (20.8, 16.2 to 26) 46 (17, 12.7 to 22)
Moderate 9 (3.3, 1.5 to 6.2) 6 (2.4, 0.9 to 5.1) 10 (3.6, 1.7 to 6.5) 12 (4.4, 2.3 to 7.6)
Severe 3 (1.1, 0.2 to 3.2) 3 (1.2, 0.2 to 3.4) 3 (1.1, 0.2 to 3.1) 4 (1.5, 0.4 to 3.7)
Any 66 (24.4, 19.4 to 30) 58 (22.8, 17.8 to 28.5) 71 (25.4, 20.4 to 31) 62 (22.9, 18 to 28.3)
Any severe symptoms 14 (5.2, 2.9 to 8.5) 19 (7.5, 4.6 to 11.4) 12 (4.3, 2.2 to 7.4) 14 (5.2, 2.9 to 8.5)
Fever ≥38°C 24 (8.9, 5.8 to 12.9)† 57 (22.4, 17.5 to 28.1)*† 26 (9.3, 6.2 to 13.4) 34 (12.5, 8.8 to 17.1)*
Any analgesic or antipyretic 85 (31.5, 26 to 37.4)† 111 (43.7, 37.5 to 50)*† 77 (27.6, 22.4 to 33.2) 64 (23.6, 18.7 to 29.1)*
*P<0.05 for comparison between vaccines.
†P<0.05 for comparison between doses.
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Table 3 | Local and systemic reactions in participants aged 5-12 years by vaccine and dose. Figures are numbers
(percentage, 95% confidence interval)
Adjuvanted split virion Whole virion
Dose 1 Dose 2 Dose 1 Dose 2
Total vaccinated 181 188 187 185
With diary card 181 176 181 175
Pain:
Mild 89 (49.2, 41.7 to 56.7) 78 (44.3, 36.8 to 52) 68 (37.6, 30.5 to 45.1) 65 (37.1, 30 to 44.8)
Moderate 44 (24.3, 18.3 to 31.2) 43 (24.4, 18.3 to 31.5) 4 (2.2, 0.6 to 5.6) 8 (4.6, 2 to 8.8)
Severe 3 (1.7, 0.3 to 4.8) 4 (2.3, 0.6 to 5.7) 0 (0, 0 to 2) 1 (0.6, 0 to 3.1)
Any 136 (75.1, 68.2 to 81.3)* 125 (71, 63.7 to 77.6)* 72 (39.8, 32.6 to 47.3)* 74 (42.3, 34.9 to 50)*
Redness (mm):
1-24 41 (22.7, 16.8 to 29.4) 40 (22.7, 16.8 to 29.6) 38 (21, 15.3 to 27.7) 34 (19.4, 13.8 to 26.1)
25-49 8 (4.4, 1.9 to 8.5) 8 (4.5, 2 to 8.8) 3 (1.7, 0.3 to 4.8) 4 (2.3, 0.6 to 5.7)
≥50 7 (3.9, 1.6 to 7.8) 9 (5.1, 2.4 to 9.5) 0 (0, 0 to 2) 0 (0, 0 to 2.1)
Any 56 (30.9, 24.3 to 38.2) 57 (32.4, 25.5 to 39.8)* 41 (22.7, 16.8 to 29.4) 38 (21.7, 15.8 to 28.6)*
Swelling:
1-24 24 (13.3, 8.7 to 19.1) 28 (15.9, 10.8 to 22.2) 21 (11.6, 7.3 to 17.2) 24 (13.7, 9 to 19.7)
25-49 9 (5, 2.3 to 9.2) 6 (3.4, 1.3 to 7.3) 2 (1.1, 0.1 to 3.9) 1 (0.6, 0 to 3.1)
≥50 8 (4.4, 1.9 to 8.5) 5 (2.8, 0.9 to 6.5) 2 (1.1, 0.1 to 3.9) 1 (0.6, 0 to 3.1)
Any 41 (22.7, 16.8 to 29.4)* 39 (22.2, 16.3 to 29) 25 (13.8, 9.1 to 19.7)* 26 (14.9, 9.9 to 21)
Any local severe 13 (7.2, 3.9 to 12)* 15 (8.5, 4.8 to 13.7)* 2 (1.1, 0.1 to 3.9)* 2 (1.1, 0.1 to 4.1)*
Loss of appetite:
Mild 33 (18.2, 12.9 to 24.6) 26 (14.8, 9.9 to 20.9) 17 (9.4, 5.6 to 14.6) 16 (9.1, 5.3 to 14.4)
Moderate 5 (2.8, 0.9 to 6.3) 5 (2.8, 0.9 to 6.5) 2 (1.1, 0.1 to 3.9) 3 (1.7, 0.4 to 4.9)
Severe 4 (2.2, 0.6 to 5.6) 2 (1.1, 0.1 to 4) 2 (1.1, 0.1 to 3.9) 1 (0.6, 0 to 3.1)
Any 42 (23.2, 17.3 to 30)* 33 (18.8, 13.3 to 25.3) 21 (11.6, 7.3 to 17.2)* 20 (11.4, 7.1 to 17.1)
Generally unwell:
Mild 39 (21.5, 15.8 to 28.3) 31 (17.6, 12.3 to 24.1) 27 (14.9, 10.1 to 21) 14 (8, 4.4 to 13.1)
Moderate 20 (11, 6.9 to 16.5) 13 (7.4, 4 to 12.3) 16 (8.8, 5.1 to 14) 12 (6.9, 3.6 to 11.7)
Severe 3 (1.7, 0.3 to 4.8) 2 (1.1, 0.1 to 4) 2 (1.1, 0.1 to 3.9) 0 (0, 0 to 2.1)
Any 62 (34.3, 27.4 to 41.7) 46 (26.1, 19.8 to 33.3)* 45 (24.9, 18.7 to 31.8)† 26 (14.9, 9.9 to 21)*†
Headache:
Mild 51 (28.2, 21.8 to 35.3) 38 (21.6, 15.8 to 28.4) 50 (27.6, 21.3 to 34.7) 36 (20.6, 14.8 to 27.3)
Moderate 25 (13.8, 9.1 to 19.7) 21 (11.9, 7.5 to 17.7) 10 (5.5, 2.7 to 9.9) 10 (5.7, 2.8 to 10.3)
Severe 1 (0.6, 0 to 3) 1 (0.6, 0 to 3.1) 1 (0.6, 0 to 3) 0 (0, 0 to 2.1)
Any 77 (42.5, 35.2 to 50.1) 60 (34.1, 27.1 to 41.6) 61 (33.7, 26.9 to 41.1) 46 (26.3, 19.9 to 33.5)
Nausea/vomiting:
Mild 30 (16.6, 11.5 to 22.8) 4 (2.2, 0.6 to 5.6) 0 (0, 0 to 2) 34 (18.8, 13.4 to 25.2)
Moderate 25 (14.2, 9.4 to 20.3) 1 (0.6, 0 to 3.1) 1 (0.6, 0 to 3.1) 27 (15.3, 10.4 to 21.5)
Severe 20 (11, 6.9 to 16.5) 1 (0.6, 0 to 3) 1 (0.6, 0 to 3) 22 (12.2, 7.8 to 17.8)
Any 15 (8.6, 4.9 to 13.7) 0 (0, 0 to 2.1) 2 (1.1, 0.1 to 4.1) 17 (9.7, 5.8 to 15.1)
Diarrhoea:
Mild 24 (13.3, 8.7 to 19.1) 11 (6.3, 3.2 to 10.9) 25 (13.8, 9.1 to 19.7) 17 (9.7, 5.8 to 15.1)
Moderate 4 (2.2, 0.6 to 5.6) 2 (1.1, 0.1 to 4) 2 (1.1, 0.1 to 3.9) 3 (1.7, 0.4 to 4.9)
Severe 0 (0, 0 to 2) 1 (0.6, 0 to 3.1) 0 (0, 0 to 2) 1 (0.6, 0 to 3.1)
Any 28 (15.5, 10.5 to 21.6)† 14 (8, 4.4 to 13)^ 27 (14.9, 10.1 to 21) 21 (12, 7.6 to 17.8)
Muscle pain:
Mild 40 (22.1, 16.3 to 28.9) 29 (16.5, 11.3 to 22.8) 22 (12.2, 7.8 to 17.8) 17 (9.7, 5.8 to 15.1)
Moderate 19 (10.5, 6.4 to 15.9) 13 (7.4, 4 to 12.3) 3 (1.7, 0.3 to 4.8) 5 (2.9, 0.9 to 6.5)
Severe 0 (0, 0 to 2) 2 (1.1, 0.1 to 4) 0 (0, 0 to 2) 0 (0, 0 to 2.1)
Any 59 (32.6, 25.8 to 39.9)* 44 (25, 18.8 to 32.1)* 25 (13.8, 9.1 to 19.7)* 22 (12.6, 8 to 18.4)*
Joint pain:
Mild 17 (9.4, 5.6 to 14.6) 15 (8.5, 4.8 to 13.7) 19 (10.5, 6.4 to 15.9) 13 (7.4, 4 to 12.4)
Moderate 3 (1.7, 0.3 to 4.8) 3 (1.7, 0.4 to 4.9) 4 (2.2, 0.6 to 5.6) 2 (1.1, 0.1 to 4.1)
Severe 0 (0, 0 to 2) 1 (0.6, 0 to 3.1) 0 (0, 0 to 2) 0 (0, 0 to 2.1)
Any 20 (11, 6.9 to 16.5) 19 (10.8, 6.6 to 16.3) 23 (12.7, 8.2 to 18.5) 15 (8.6, 4.9 to 13.7)
Any severe symptoms 5 (2.8, 0.9 to 6.3) 5 (2.8, 0.9 to 6.5) 3 (1.7, 0.3 to 4.8) 2 (1.1, 0.1 to 4.1)
Fever ≥38°C 14 (7.7, 4.3 to 12.6) 11 (6.3, 3.2 to 10.9) 6 (3.3, 1.2 to 7.1) 5 (2.9, 0.9 to 6.5)
Any analgesic/antipyretic 66 (36.5, 29.5 to 43.9)* 50 (28.4, 21.9 to 35.7)* 40 (22.1, 16.3 to 28.9)* 29 (16.6, 11.4 to 22.9)*
*P<0.05 for comparison between vaccines.
†P<0.05 for comparison between doses.
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a 3% decrease in titre per year of age (0.5% to 5%,
P=0.02) for the split virion adjuvanted vaccine and a
16% increase per year (12% to 21%, P<0.001) for the
whole virion vaccine.
DISCUSSION
In this head to head study of an adjuvanted split virion
H1N1 pandemic vaccine and a non-adjuvanted whole
virion vaccine in children, both vaccines were well tol-
erated. The vaccine containing the novel adjuvant was
more immunogenic than the whole virion vaccine,
especially in young children, but was alsomore reacto-
genic.
In the UK, most influenza activity in 2009-10 has
been caused by pandemic influenzaA (H1N1). Serolo-
gical evidence has shown low levels of immunity in
children before the pandemic and correspondingly
high attack rates.1 A UK vaccination programme,
principally using the adjuvanted split virion
vaccine,23 was announced in August 2009, initially tar-
geting those with comorbidities, but was widened to all
children aged 6 months to 5 years in December 2009
after a review of interim data from this study and other
data.23
A recent serosurvey showed that the rates of H1N1
infection in English children after the first wave of the
pandemic (as measured by haemagglutination inhibi-
tion titres ≥1:32) were higher than the 3.5% observed
before immunisation in our study.1 This could reflect
geographical differences in exposure risk1 and our
exclusion of children with a history of confirmed
H1N1 disease and those treated for suspected infec-
tion. Follow-up took place during the second wave of
the UK pandemic, but any boosting effect of natural
infectionwould be expected to be similar between vac-
cine groups.
Immunogenicity
The immunogenicity of both seasonal influenza
vaccines7 and other, non-adjuvanted, H1N1
vaccines11 in young children is less than in older chil-
dren and adults. New generation adjuvants (such as
MF59 and AS03B) have been used to improve
immunogenicity,13 14 24 though paediatric experience
with these adjuvants is limited and AS03B has pre-
viously been used only in the H5N1 mock-up pan-
demic vaccine. In our study the adjuvanted split
virion vaccine was highly immunogenic, even in
young children, but was slightly less immunogenic in
older children than in infants (3% per year with age), a
pattern not previously described for inactivated vac-
cines. We also found a strongly age dependent
response to the whole virion vaccine, with 15% higher
immunogenicity per year with age. Other H1N1 vac-
cines, including both adjuvanted and non-adjuvanted
vaccines, are immunogenic in children but contain
considerably more antigen than the adjuvanted split
virion vaccine used in this trial.10 25 Antigen sparing is
important in a pandemic setting where requirements
for vaccine exceed manufacturing capability.26 H5N1
vaccine trials before the pandemic showed the need for
a two dose regimen in immunologically naive
individuals,19 and two dose regimens of several
H1N1 vaccines are more immunogenic than single
dose regimens.10 11 25 Limited data, however, have
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Fig 2 | Reverse cumulative distribution curves of antibody
titres as measured by microneutralisation curves and
haemagglutination inhibition assays by age group and
vaccine
Table 4 | Seroconversion by microneutralisation titre (95% confidence interval)
Vaccine and age (years)
Before vaccine After second dose Rise
No Titre % ≥1:40 No Titre %≥1:40 No Titre % ≥ fourfold to ≥1:40
Whole virion
<3 9/216 4.2 (1.9 to 7.8) 166/206 80.6 (74.5 to 85.8) 157/196 80.1 (73.8 to 85.5)
3-12 11/240 4.6 (2.3 to 8.1) 211/220 95.9 (92.4 to 98.1) 208/217 95.9 (92.4 to 98.1)
All 20/456 4.4 (2.7 to 6.7) 377/426 88.5 (85.1 to 91.3) 365/413 88.4 (84.9 to 91.3)
Adjuvanted split virion
<3 3/191 1.6 (0.3 to 4.5) 175/177 98.9 (96.0 to 99.9) 163/166 98.2 (94.8 to 99.6)
3-12 13/244 5.3 (2.9 to 8.9) 234/235 99.6 (97.7 to 99.9) 226/228 99.1 (96.9 to 99.9)
All 16/435 3.7 (2.1 to 5.9) 409/412 99.3 (97.9 to 99.8) 389/394 98.7 (97.1 to 99.6)
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suggested that the adjuvanted split virion vaccine used
in our trial might be sufficient to meet licensing
criteria,12 19 and the UK has recently recommended a
single dose regimen in healthy children.23 Further stu-
dies evaluating the breadth and duration of the
immune response to single and two dose regimens are
needed.14
Even during periods between pandemics, children
experience considerable morbidity and mortality
from influenza infection, and their role in virus trans-
mission results in a much wider burden.7 Unlike the
UK, some countries recommend that all children are
routinely immunised against seasonal influenza,6
although the available vaccines have low immunogeni-
city in young children.7 The favourable immunogeni-
city of the adjuvanted split virion vaccine in the
youngest children in our study suggests that novel
adjuvants could be used to improve the immunogeni-
city of seasonal influenza vaccines in this population.
Reactogenicity
Whole virion influenza vaccines have previously been
associated with high reactogenicity rates.7 We have
shown that a whole virion H1N1 vaccine in children
is well tolerated. Increased reactogenicity was seen
with an MF59 adjuvanted H1N1 vaccine in children27
as well as in adult trials of oil in water adjuvanted
vaccines.12-15 24 The AS03B adjuvanted vaccine in this
trial was similarly associated with more local reactions
and some increase in systemic reactions compared
with whole virion vaccine.Our observed local and sys-
temic rates of reactogenicity were generally in keeping
with data in the summaryof product characteristics.12 19
Though we found the rate of fever to be slightly higher
in infants after the second dose comparedwith the first,
this was half the rate reported in the product character-
istics (43% of 51 infants).19
Strengths and limitations of the study
Children with comorbidities are at increased risk of
severe H1N1 disease, and for this reason we did not
exclude children with pre-existing medical conditions
(except immunodeficiency), making our findings par-
ticularly relevant to the general paediatric population.
The haemagglutination inhibition assay is used
extensively in the serological assessment of immunity
to influenza viruses and as a criterion for
licensing.21 28-30 However, it measures antibody direc-
ted only to the receptor binding site, while the micro-
neutralisation assay might be more sensitive as it
detects antibody directed to this and other antigenic
sites in the virus24 28 31 and was therefore chosen as the
primary immunogenicity end point.
When we were designing this study, a two dose pan-
demic vaccine schedule was planned for children, and
for this reason our pragmatic trial did not include a
blood test after one dose to simplify the study in the
face of the need for rapid recruitment. With the subse-
quent change to a single dose regimen in the UK, our
results would have been strengthened by addition of
assessment of immunogenicity after a single dose.
Furthermore, a comparison with a non-adjuvanted
split virion vaccine would be of interest but none was
used in the UK during the 2009 H1N1 pandemic, and
we limited the study to these two novel vaccines.
Table 5 | Seroconversion by haemagglutination inhibition titre
Vaccine and age (years)
Before vaccine After second dose Rise
No Titre % ≥1:32 No Titre % ≥1:32 No Titre % ≥ fourfold to ≥1:32
Whole virion
<3 years 8/216 3.7 (1.6 to 7.2) 136/207 65.7 (58.8 to 72.1) 126/197 64.0 (56.8 to 70.7)
3-12 7/240 2.9 (1.2 to 5.9) 198/220 90.0 (85.3 to 93.6) 192/217 88.5 (83.5 to 92.4)
All 15/456 3.3 (1.9 to 5.4) 334/427 78.2 (74.0 to 82.0) 318/414 76.8 (72.4 to 80.8)
Adjuvanted split virion
<3 3/191 1.6 (0.3 to 4.5) 174/175 99.4 (96.9 to 99.9) 163/164 99.4 (96.6 to 99.9)
3-12 13/244 5.3 (2.9 to 8.9) 233/235 99.1 (97.0 to 99.9) 225/228 98.7 (96.2 to 99.7)
All 16/435 3.7 (2.1 to 5.9) 407/410 99.3 (97.9 to 99.8) 388/392 99.0 (97.4 to 99.7)
Table 6 | Haemagglutination inhibition geometric mean titres
Vaccine and age (years)
Before vaccine After second dose Rise
No Titre No Titre No Titre
Whole virion
<3 216 4.6 (4.2 to 5.1) 207 44.0 (35.6 to 54.3) 197 9.5 (7.8 to 11.6)
3-12 240 4.6 (4.2 to 4.9) 220 106.3 (90.2 to 125.3) 217 22.7 (19.3 to 26.8)
All 456 4.6 (4.3 to 4.9) 427 69.3 (60.3 to 79.6) 414 15.0 (13.2 to 17.2)
Adjuvanted split virion
<3 191 4.2 (4.0 to 4.5) 175 461.0 (409.0 to 519.6) 164 107.4 (93.9 to 122.9)
3-12 244 4.8 (4.3 to 5.3) 235 377.3 (339.2 to 419.7) 228 78.5 (69.9 to 88.1)
All 435 4.5 (4.3 to 4.8) 410 411.0 (379.4 to 445.2) 392 89.5 (81.9 to 97.8)
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Conclusions and policy implications
In this direct comparison of two commercially avail-
able novelH1N1 vaccines, AS03B adjuvanted split vir-
ion vaccine was more immunogenic and induced high
seroconversion rates in young children. These data
provide important information to guide immunisation
policy in an influenza pandemic and indicate the
potential for improved immunogenicity of seasonal
influenza vaccines in children.
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